Drug resistance in multiple myeloma: Cyclosporin A analogues and their metabolites as potential chemosensitizers

Leukemia

Volumn 12, Issue 4, 1998, Pages 505-509

  Pilarski, L M ^a   Yatscoff, R W ^a   Murphy, G F ^b   Belch, A R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Novartis Pharmaceuticals Canada Inc   (Canada)

Author keywords

B cells; Cyclosporins; Drug resistance; Dye efflux; Multiple myeloma

Indexed keywords

CYCLOSPORIN A; CYCLOSPORIN G; RHODAMINE 123; SDZ 280446; VALSPODAR;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TRANSPORT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0031970208     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400984     Document Type: Article

References (31)

1. Dalton WS, Grogan TM, Meltzer PS et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-424.
2. Sonneveld P, Durie BGM, Lokhorst HM et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Effects of a novel immunosuppressive agent, FK506, on human B cell activation. Lancet 1992; 340: 255-259.
3. Sonneveld P, Marie JP, Lokhorst HM, Nooter K, Schoester M. Clinical modulation of multidrug resistance in VAD-refractory myeloma: studies with cyclosporin and SDZ PSC 833. Anti-Cancer Drugs 1994; 5 (Suppl. 1): 72.
4. Twentyman PR. Modification of multidrug resistance. Br J Haematol 1995; 90: 735-737.
5. Pilarski LM, Szczepek AJ, Belch AR. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood 1997; 90: 3751-3759.
6. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ rearrangements. Blood 1997; 89: 1824-1833.
7. Pilarski LM, Belch AJ. Circulating monoclonal B cells expressing p-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood 1994; 83: 724-736.
8. Grogan TM, Spier CM, Salmon SE et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490-495.
9. Sonneveld P, Durie BGM, Lokhorst HM, Frutiger Y, Schoester M, Vela EE. Analysis of multidrug resistance (mdr-1) p-glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Br J Haematol 1993; 83: 63-67.
10. Borst P. Genetic mechanisms of drug resistance. Rev Oncol 1991; 4: 87-105.
11. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 385-427.
12. Endicott JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Ann Rev Biochem 1989; 58: 137-171.
13. Cole SP, Bhardwaj G, Gerlach JH et al. Overexpression of a trans-porter gene in a multidrug resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
14. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 1994; 54: 4676-4679.
15. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-2458.
16. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735-2793.
17. Chaudhary PM, Roninson IB. Expression and activity of p-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
18. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P-gp 170: evidence for localization in brain capillaries and cross reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159-164.
19. Arceci RJ, Croop JM, Horwitz SB, Hourman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988; 85: 4350-4354.
20. Pilarski LM, Belch AR. Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma; implications for treatment. Leuk Lymphoma 1995; 17: 367-374.
21. Yatscoff RW, Rosano TG, Bower LD. The clinical significance of cyclosporine metabolites. Clin Biochem 1991; 24: 23-35.
22. Copeland KR, Yatscoff RW, McKenna RM. Immunosuppressive activity of cyclosporin metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clin Chem 1990; 36: 225-229.
23. Uwe C, Sewing KF. Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 1995; 28: 547-559.
24. Pourtier-Manzanedo A, Didier AD, Muller CD, Loor F. SDZ PSC 833 and SDZ 280 446 are the most active of various resistance modifying agents in restoring rhodamine 123 retention within multidrug resistant P388 cells. Anticancer Drugs 1992; 3: 419-425.
25. Jachez B, Nordmann R, Loor F. Restoration of taxol sensitivity of multidrug resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 1993; 85: 478-483.
26. Copeland KR, Yatscoff RW. The isolation, structural characterization and immunosuppressive activity of cyclosporin G (NVa2 cyclosporin) metabolites. Ther Drug Monit 1991; 13: 281-288.
27. Bergsagel PL, Masellis S, Szczepek A, Mant MJ, Belch AR, Pilarski LM. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing C38, CD5G and monotypic immunoglobulin light chain. Blood 1995; 85: 436-447.
28. Belch AR, Szczepek AR, Pilarski LM. Drug-resistant malignant B cells in multiple myeloma express CD11b and clonotypic transcripts. Blood 1997; 90: 526a.
29. Langman LJ, Leichtman AB, Weitzel WF, Yatscoff RW. Steady-state concentration of cyclosporin G (OG37-325) and its metabolites in renal transplant recipients. Clin Chem 1994; 40: 613-661.
30. Kuzendorf U, Walz G, Brockmoeller J et al. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation 1991; 52: 280-284.
31. Pilarski LM, Szczepek AJ, Mant MJ, Belch AR. Cryptic expression of the CD19 epitope detected by mAb Leu12 distinguishes malignant from residual polyclonal B cells in the blood of myeloma patients. Blood 1997; 90: 349a.